Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report
Abstract Background Waldenström’s macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström’s macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | Journal of Medical Case Reports |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13256-018-1694-z |
| _version_ | 1818766046395367424 |
|---|---|
| author | M. D’Aveni-Piney M. Divoux H. Busby-Venner M. Muller J. Broséus P. Feugier |
| author_facet | M. D’Aveni-Piney M. Divoux H. Busby-Venner M. Muller J. Broséus P. Feugier |
| author_sort | M. D’Aveni-Piney |
| collection | DOAJ |
| description | Abstract Background Waldenström’s macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström’s macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but not idelalisib) is currently approved for treatment of patients with relapsed or refractory Waldenström’s macroglobulinemia. Case presentation We report a case of a 71-year-old white French man with Waldenström’s macroglobulinemia who presented with acute renal failure and hyperviscosity syndrome. His Waldenström’s macroglobulinemia was refractory to first-line treatment with rituximab, cyclophosphamide, and dexamethasone. Because of his hemorrhagic syndrome and medical history of recent myocardial infarction, we decided to treat him with idelalisib 150 mg twice daily instead of ibrutinib. We observed a very quick improvement in the patient’s clinical status without need for dose adjustment. Conclusion Our patient’s case provides the first evidence, to the best of our knowledge, that idelalisib may be an efficient treatment option for patients with Waldenström’s macroglobulinemia complicated by anuric renal failure and in whom ibrutinib is contraindicated. |
| first_indexed | 2024-12-18T08:27:45Z |
| format | Article |
| id | doaj.art-f283a835005f4b6d8958b9758ef1fa30 |
| institution | Directory Open Access Journal |
| issn | 1752-1947 |
| language | English |
| last_indexed | 2024-12-18T08:27:45Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Medical Case Reports |
| spelling | doaj.art-f283a835005f4b6d8958b9758ef1fa302022-12-21T21:14:33ZengBMCJournal of Medical Case Reports1752-19472018-06-011211610.1186/s13256-018-1694-zIdelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case reportM. D’Aveni-Piney0M. Divoux1H. Busby-Venner2M. Muller3J. Broséus4P. Feugier5Hematology Department, University Hospital of NancyHematology Department, University Hospital of NancyDepartment of Pathology, University Hospital of NancyGenetics Laboratory, University Hospital of NancyBiological Laboratory, University Hospital of NancyHematology Department, University Hospital of NancyAbstract Background Waldenström’s macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström’s macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but not idelalisib) is currently approved for treatment of patients with relapsed or refractory Waldenström’s macroglobulinemia. Case presentation We report a case of a 71-year-old white French man with Waldenström’s macroglobulinemia who presented with acute renal failure and hyperviscosity syndrome. His Waldenström’s macroglobulinemia was refractory to first-line treatment with rituximab, cyclophosphamide, and dexamethasone. Because of his hemorrhagic syndrome and medical history of recent myocardial infarction, we decided to treat him with idelalisib 150 mg twice daily instead of ibrutinib. We observed a very quick improvement in the patient’s clinical status without need for dose adjustment. Conclusion Our patient’s case provides the first evidence, to the best of our knowledge, that idelalisib may be an efficient treatment option for patients with Waldenström’s macroglobulinemia complicated by anuric renal failure and in whom ibrutinib is contraindicated.http://link.springer.com/article/10.1186/s13256-018-1694-zWaldenström’s macroglobulinemiaIdelalisibAnuric renal failure |
| spellingShingle | M. D’Aveni-Piney M. Divoux H. Busby-Venner M. Muller J. Broséus P. Feugier Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report Journal of Medical Case Reports Waldenström’s macroglobulinemia Idelalisib Anuric renal failure |
| title | Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report |
| title_full | Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report |
| title_fullStr | Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report |
| title_full_unstemmed | Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report |
| title_short | Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report |
| title_sort | idelalisib in a patient with refractory waldenstrom s macroglobulinemia complicated by anuric renal failure a case report |
| topic | Waldenström’s macroglobulinemia Idelalisib Anuric renal failure |
| url | http://link.springer.com/article/10.1186/s13256-018-1694-z |
| work_keys_str_mv | AT mdavenipiney idelalisibinapatientwithrefractorywaldenstromsmacroglobulinemiacomplicatedbyanuricrenalfailureacasereport AT mdivoux idelalisibinapatientwithrefractorywaldenstromsmacroglobulinemiacomplicatedbyanuricrenalfailureacasereport AT hbusbyvenner idelalisibinapatientwithrefractorywaldenstromsmacroglobulinemiacomplicatedbyanuricrenalfailureacasereport AT mmuller idelalisibinapatientwithrefractorywaldenstromsmacroglobulinemiacomplicatedbyanuricrenalfailureacasereport AT jbroseus idelalisibinapatientwithrefractorywaldenstromsmacroglobulinemiacomplicatedbyanuricrenalfailureacasereport AT pfeugier idelalisibinapatientwithrefractorywaldenstromsmacroglobulinemiacomplicatedbyanuricrenalfailureacasereport |